Global Paclitaxel Injection

Paclitaxel Injection Comprehensive Study by Application (Ovarian cancer, Breast cancer, Cervical cancer, Pancreatic cancer, Other), Strength (30 mg (5 mL), 100 mg (16.7 mL), 300 mg (50 mL)), End User (Hospitals, Clincs) Players and Region - Global Market Outlook to 2026

Paclitaxel Injection Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Paclitaxel Injection Market Scope?
Paclitaxel is a chemotherapy medicine. It targets fast-breaking cells, like cancer cells, and causes these cells to die. This drug is utilized to administer ovarian cancer, breast cancer, lung cancer, Kaposi's sarcoma, and other cancers. It is obtained from Pacific yew trees, after the chemical synthesis process. It’s a Segment of antineoplastic drug class, practiced to cure cancer in the breast, lungs, ovaries, stomach, cervix, and others.

The Paclitaxel Injection market study is being classified, by Application (Ovarian cancer, Breast cancer, Cervical cancer, Pancreatic cancer and Other) and major geographies with country level break-up.

The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Paclitaxel Injection market throughout the predicted period.

Bristol-Myers Squibb (United States), Celgene Corporation (United States), Hospira (United States), Biological E. (United States), Taj Accura (Ireland), Khandelwal Laboratories (India), Luye Pharma (China) and Haiyao (China) are some of the key players profiled in the study.

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Paclitaxel Injection market by Type, Application and Region.

On the basis of geography, the market of Paclitaxel Injection has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).




Influencing Market Trend
  • Increasing government body support for cancer

Market Drivers
  • The increasing prevalence of cancer
  • Increasing population and increasing disease incidence of ovarian cancer

Opportunities
  • The growing population and increasing disease incidence

Restraints
  • The adverse effect of the paclitaxel injection

Challenges
  • . The high cost of drug


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Paclitaxel Injection Manufacturer, Raw Material Suppliers, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Report Objectives / Segmentation Covered

By Application
  • Ovarian cancer
  • Breast cancer
  • Cervical cancer
  • Pancreatic cancer
  • Other
By Strength
  • 30 mg (5 mL)
  • 100 mg (16.7 mL)
  • 300 mg (50 mL)

By End User
  • Hospitals
  • Clincs

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The increasing prevalence of cancer
      • 3.2.2. Increasing population and increasing disease incidence of ovarian cancer
    • 3.3. Market Challenges
      • 3.3.1. . The high cost of drug
    • 3.4. Market Trends
      • 3.4.1. Increasing government body support for cancer
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Paclitaxel Injection, by Application, Strength, End User and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Paclitaxel Injection (Value)
      • 5.2.1. Global Paclitaxel Injection by: Application (Value)
        • 5.2.1.1. Ovarian cancer
        • 5.2.1.2. Breast cancer
        • 5.2.1.3. Cervical cancer
        • 5.2.1.4. Pancreatic cancer
        • 5.2.1.5. Other
      • 5.2.2. Global Paclitaxel Injection by: Strength (Value)
        • 5.2.2.1. 30 mg (5 mL)
        • 5.2.2.2. 100 mg (16.7 mL)
        • 5.2.2.3. 300 mg (50 mL)
      • 5.2.3. Global Paclitaxel Injection by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clincs
      • 5.2.4. Global Paclitaxel Injection Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Paclitaxel Injection: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol-Myers Squibb (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Celgene Corporation (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Hospira (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Biological E. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Taj Accura (Ireland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Khandelwal Laboratories (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Luye Pharma (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Haiyao (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Paclitaxel Injection Sale, by Application, Strength, End User and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Paclitaxel Injection (Value)
      • 7.2.1. Global Paclitaxel Injection by: Application (Value)
        • 7.2.1.1. Ovarian cancer
        • 7.2.1.2. Breast cancer
        • 7.2.1.3. Cervical cancer
        • 7.2.1.4. Pancreatic cancer
        • 7.2.1.5. Other
      • 7.2.2. Global Paclitaxel Injection by: Strength (Value)
        • 7.2.2.1. 30 mg (5 mL)
        • 7.2.2.2. 100 mg (16.7 mL)
        • 7.2.2.3. 300 mg (50 mL)
      • 7.2.3. Global Paclitaxel Injection by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clincs
      • 7.2.4. Global Paclitaxel Injection Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Paclitaxel Injection: by Application(USD Million)
  • Table 2. Paclitaxel Injection Ovarian cancer , by Region USD Million (2015-2020)
  • Table 3. Paclitaxel Injection Breast cancer , by Region USD Million (2015-2020)
  • Table 4. Paclitaxel Injection Cervical cancer , by Region USD Million (2015-2020)
  • Table 5. Paclitaxel Injection Pancreatic cancer , by Region USD Million (2015-2020)
  • Table 6. Paclitaxel Injection Other , by Region USD Million (2015-2020)
  • Table 7. Paclitaxel Injection: by Strength(USD Million)
  • Table 8. Paclitaxel Injection 30 mg (5 mL) , by Region USD Million (2015-2020)
  • Table 9. Paclitaxel Injection 100 mg (16.7 mL) , by Region USD Million (2015-2020)
  • Table 10. Paclitaxel Injection 300 mg (50 mL) , by Region USD Million (2015-2020)
  • Table 11. Paclitaxel Injection: by End User(USD Million)
  • Table 12. Paclitaxel Injection Hospitals , by Region USD Million (2015-2020)
  • Table 13. Paclitaxel Injection Clincs , by Region USD Million (2015-2020)
  • Table 14. South America Paclitaxel Injection, by Country USD Million (2015-2020)
  • Table 15. South America Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 16. South America Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 17. South America Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 18. Brazil Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 19. Brazil Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 20. Brazil Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 21. Argentina Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 22. Argentina Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 23. Argentina Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 24. Rest of South America Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 25. Rest of South America Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 26. Rest of South America Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 27. Asia Pacific Paclitaxel Injection, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 29. Asia Pacific Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 30. Asia Pacific Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 31. China Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 32. China Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 33. China Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 34. Japan Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 35. Japan Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 36. Japan Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 37. India Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 38. India Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 39. India Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 40. South Korea Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 41. South Korea Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 42. South Korea Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 43. Taiwan Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 44. Taiwan Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 45. Taiwan Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 46. Australia Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 47. Australia Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 48. Australia Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 52. Europe Paclitaxel Injection, by Country USD Million (2015-2020)
  • Table 53. Europe Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 54. Europe Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 55. Europe Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 56. Germany Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 57. Germany Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 58. Germany Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 59. France Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 60. France Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 61. France Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 62. Italy Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 63. Italy Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 64. Italy Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 65. United Kingdom Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 66. United Kingdom Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 67. United Kingdom Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 68. Netherlands Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 69. Netherlands Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 70. Netherlands Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 71. Rest of Europe Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 72. Rest of Europe Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 73. Rest of Europe Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 74. MEA Paclitaxel Injection, by Country USD Million (2015-2020)
  • Table 75. MEA Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 76. MEA Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 77. MEA Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 78. Middle East Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 79. Middle East Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 80. Middle East Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 81. Africa Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 82. Africa Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 83. Africa Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 84. North America Paclitaxel Injection, by Country USD Million (2015-2020)
  • Table 85. North America Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 86. North America Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 87. North America Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 88. United States Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 89. United States Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 90. United States Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 91. Canada Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 92. Canada Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 93. Canada Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 94. Mexico Paclitaxel Injection, by Application USD Million (2015-2020)
  • Table 95. Mexico Paclitaxel Injection, by Strength USD Million (2015-2020)
  • Table 96. Mexico Paclitaxel Injection, by End User USD Million (2015-2020)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Paclitaxel Injection: by Application(USD Million)
  • Table 106. Paclitaxel Injection Ovarian cancer , by Region USD Million (2021-2026)
  • Table 107. Paclitaxel Injection Breast cancer , by Region USD Million (2021-2026)
  • Table 108. Paclitaxel Injection Cervical cancer , by Region USD Million (2021-2026)
  • Table 109. Paclitaxel Injection Pancreatic cancer , by Region USD Million (2021-2026)
  • Table 110. Paclitaxel Injection Other , by Region USD Million (2021-2026)
  • Table 111. Paclitaxel Injection: by Strength(USD Million)
  • Table 112. Paclitaxel Injection 30 mg (5 mL) , by Region USD Million (2021-2026)
  • Table 113. Paclitaxel Injection 100 mg (16.7 mL) , by Region USD Million (2021-2026)
  • Table 114. Paclitaxel Injection 300 mg (50 mL) , by Region USD Million (2021-2026)
  • Table 115. Paclitaxel Injection: by End User(USD Million)
  • Table 116. Paclitaxel Injection Hospitals , by Region USD Million (2021-2026)
  • Table 117. Paclitaxel Injection Clincs , by Region USD Million (2021-2026)
  • Table 118. South America Paclitaxel Injection, by Country USD Million (2021-2026)
  • Table 119. South America Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 120. South America Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 121. South America Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 122. Brazil Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 123. Brazil Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 124. Brazil Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 125. Argentina Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 126. Argentina Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 127. Argentina Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 128. Rest of South America Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 129. Rest of South America Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 130. Rest of South America Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 131. Asia Pacific Paclitaxel Injection, by Country USD Million (2021-2026)
  • Table 132. Asia Pacific Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 133. Asia Pacific Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 134. Asia Pacific Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 135. China Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 136. China Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 137. China Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 138. Japan Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 139. Japan Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 140. Japan Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 141. India Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 142. India Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 143. India Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 144. South Korea Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 145. South Korea Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 146. South Korea Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 147. Taiwan Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 148. Taiwan Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 149. Taiwan Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 150. Australia Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 151. Australia Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 152. Australia Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 153. Rest of Asia-Pacific Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 154. Rest of Asia-Pacific Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 155. Rest of Asia-Pacific Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 156. Europe Paclitaxel Injection, by Country USD Million (2021-2026)
  • Table 157. Europe Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 158. Europe Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 159. Europe Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 160. Germany Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 161. Germany Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 162. Germany Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 163. France Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 164. France Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 165. France Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 166. Italy Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 167. Italy Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 168. Italy Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 169. United Kingdom Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 170. United Kingdom Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 171. United Kingdom Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 172. Netherlands Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 173. Netherlands Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 174. Netherlands Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 175. Rest of Europe Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 176. Rest of Europe Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 177. Rest of Europe Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 178. MEA Paclitaxel Injection, by Country USD Million (2021-2026)
  • Table 179. MEA Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 180. MEA Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 181. MEA Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 182. Middle East Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 183. Middle East Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 184. Middle East Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 185. Africa Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 186. Africa Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 187. Africa Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 188. North America Paclitaxel Injection, by Country USD Million (2021-2026)
  • Table 189. North America Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 190. North America Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 191. North America Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 192. United States Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 193. United States Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 194. United States Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 195. Canada Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 196. Canada Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 197. Canada Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 198. Mexico Paclitaxel Injection, by Application USD Million (2021-2026)
  • Table 199. Mexico Paclitaxel Injection, by Strength USD Million (2021-2026)
  • Table 200. Mexico Paclitaxel Injection, by End User USD Million (2021-2026)
  • Table 201. Research Programs/Design for This Report
  • Table 202. Key Data Information from Secondary Sources
  • Table 203. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Paclitaxel Injection: by Application USD Million (2015-2020)
  • Figure 5. Global Paclitaxel Injection: by Strength USD Million (2015-2020)
  • Figure 6. Global Paclitaxel Injection: by End User USD Million (2015-2020)
  • Figure 7. South America Paclitaxel Injection Share (%), by Country
  • Figure 8. Asia Pacific Paclitaxel Injection Share (%), by Country
  • Figure 9. Europe Paclitaxel Injection Share (%), by Country
  • Figure 10. MEA Paclitaxel Injection Share (%), by Country
  • Figure 11. North America Paclitaxel Injection Share (%), by Country
  • Figure 12. Global Paclitaxel Injection share by Players 2020 (%)
  • Figure 13. Global Paclitaxel Injection share by Players (Top 3) 2020(%)
  • Figure 14. Global Paclitaxel Injection share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 17. Bristol-Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 18. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 19. Celgene Corporation (United States) Revenue: by Geography 2020
  • Figure 20. Hospira (United States) Revenue, Net Income and Gross profit
  • Figure 21. Hospira (United States) Revenue: by Geography 2020
  • Figure 22. Biological E. (United States) Revenue, Net Income and Gross profit
  • Figure 23. Biological E. (United States) Revenue: by Geography 2020
  • Figure 24. Taj Accura (Ireland) Revenue, Net Income and Gross profit
  • Figure 25. Taj Accura (Ireland) Revenue: by Geography 2020
  • Figure 26. Khandelwal Laboratories (India) Revenue, Net Income and Gross profit
  • Figure 27. Khandelwal Laboratories (India) Revenue: by Geography 2020
  • Figure 28. Luye Pharma (China) Revenue, Net Income and Gross profit
  • Figure 29. Luye Pharma (China) Revenue: by Geography 2020
  • Figure 30. Haiyao (China) Revenue, Net Income and Gross profit
  • Figure 31. Haiyao (China) Revenue: by Geography 2020
  • Figure 32. Global Paclitaxel Injection: by Application USD Million (2021-2026)
  • Figure 33. Global Paclitaxel Injection: by Strength USD Million (2021-2026)
  • Figure 34. Global Paclitaxel Injection: by End User USD Million (2021-2026)
  • Figure 35. South America Paclitaxel Injection Share (%), by Country
  • Figure 36. Asia Pacific Paclitaxel Injection Share (%), by Country
  • Figure 37. Europe Paclitaxel Injection Share (%), by Country
  • Figure 38. MEA Paclitaxel Injection Share (%), by Country
  • Figure 39. North America Paclitaxel Injection Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bristol-Myers Squibb (United States)
  • Celgene Corporation (United States)
  • Hospira (United States)
  • Biological E. (United States)
  • Taj Accura (Ireland)
  • Khandelwal Laboratories (India)
  • Luye Pharma (China)
  • Haiyao (China)
Select User Access Type

Key Highlights of Report


Apr 2021 249 Pages 62 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Paclitaxel Injection Quantitative research analysis
Global Paclitaxel Injection Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Global Paclitaxel Injection market is expected to see a growth of % during projected year 2020 to 2026.
The prominent players of Global Paclitaxel Injection market are Bristol-Myers Squibb (United States), Celgene Corporation (United States), Hospira (United States), Biological E. (United States), Taj Accura (Ireland), Khandelwal Laboratories (India), Luye Pharma (China) and Haiyao (China), to name a few.
In this highly competitive & fast evolving Paclitaxel Injection industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.

Know More About Global Paclitaxel Injection Report?

Have a Query? Click Here

Other Related Reports

Primary Hyperoxaluria Drug Comprehensive Study by Type (ALLN-230, DCR-PHXC, ALN-GO1, Others), Application (Hospital, Clinic, Others), Drug types (Primary hyperoxaluria type III (PH III), Primary hype...
$ 3450
Cancer Immunotherapies Comprehensive Study by End-User (Healthcare Sector, Pharmaceutical, Cancer Research Centre, Laboratory, Others), Cancer Type (Bladder Cancer, Brain Cancer, Cervical Cancer, Hea...
$ 3350
Central Venous Catheter Comprehensive Study by Type (Peripherally Inserted Central Venous Catheter, Tunneled Central Venous Catheter, Non-tunneled Central Venous Catheter), Application (Kidney Dialys...
$ 3750
Pancreatitis Drugs Comprehensive Study by Application (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Drug Form (Tablets, Capsule), Pancreatitis (Acute Pancreatitis, Chronic Pancreatitis), End...
$ 3450
Glucomannan Extract Comprehensive Study by Type (Glucomannan 75%, Glucomannan 80%, Glucomannan 90%), Application (Food Industry, Pharmaceutical Industry, Healthy Products Industry), Form (Tablet, Pow...
$ 3450
Leuprolide Acetate Comprehensive Study by Type (Intramuscular, Subcutaneous), Application (Prostate Cancer, Precocious, Uterine Fibroid, Others) Players and Region - Global Market Outlook to 2027
$ 3500